{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:10:04Z","timestamp":1783782604927,"version":"3.55.0"},"reference-count":12,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Seagen Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Brentuximab vedotin (BV) monotherapy (BV-M) and combination (BV-C) therapies are safe and effective for classical Hodgkin lymphoma (cHL) and CD30-expressing peripheral T-cell lymphomas (PTCLs). Although the sample sizes have been small (12\u201329 patients), in clinical studies, response rates of 53\u201388% have been reported for BV retreatment in patients with an initial BV response. We evaluated the real-world characteristics and treatment patterns of cHL\/PTCL patients who received BV and were retreated in the United States. Symphony Health Patient Claims (11\/2013\u20131\/2022) were retrospectively analyzed to identify cHL\/PTCL patients treated with BV and retreated with BV-M, BV-C, or non-BV therapy. Patient characteristics were described by retreatment, and predictors of BV-M retreatment were identified. Among the cHL and PTCL patients treated with BV (n = 6442 and 2472, respectively), 13% and 12%, respectively, were retreated with BV; the median times from initial BV to BV-M retreatment were 5 and 7 months, respectively; and the numbers of BV-M retreatment doses were 4 and 5, respectively. Among cHL patients, the predictors of BV-M retreatment were age (18\u201339 vs. \u226560 years), sex (women vs. men), and previous stem cell transplantation (yes vs. no). Among PTCL patients, the only predictor of BV-M retreatment was systemic anaplastic large-cell lymphoma subtype (yes vs. no). Real-world data support clinical study results suggesting earlier BV treatment be considered, as BV retreatment may be an option.<\/jats:p>","DOI":"10.3390\/curroncol31050195","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T03:43:46Z","timestamp":1714707826000},"page":"2598-2609","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis"],"prefix":"10.3390","volume":"31","author":[{"given":"Dahlia","family":"Sano","sequence":"first","affiliation":[{"name":"1500 East Medical Center Dr., University of Michigan, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Liu","sequence":"additional","affiliation":[{"name":"Pfizer Inc., 21823 30th Drive SE, Bothell, WA 98021, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Knowles","sequence":"additional","affiliation":[{"name":"Pfizer Inc., 21823 30th Drive SE, Bothell, WA 98021, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna P.","family":"MacEwan","sequence":"additional","affiliation":[{"name":"Genesis Research, 111 River St., Hoboken, NJ 07030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Wang","sequence":"additional","affiliation":[{"name":"Genesis Research, 111 River St., Hoboken, NJ 07030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenifer","family":"Wogen","sequence":"additional","affiliation":[{"name":"Genesis Research, 111 River St., Hoboken, NJ 07030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina S.","family":"Yu","sequence":"additional","affiliation":[{"name":"Pfizer Inc., 21823 30th Drive SE, Bothell, WA 98021, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Tae","family":"Lee","sequence":"additional","affiliation":[{"name":"Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 22 South Greene St. S9D04A, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"ref_1","unstructured":"(2023). ADCETRIS [Package Insert], Seagen Inc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/10428194.2019.1654100","article-title":"Retreatment with brentuximab vedotin in patients with relapsed\/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: A multicenter retrospective study","volume":"61","author":"Fukuhara","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"12003","DOI":"10.1182\/blood-2022-158225","article-title":"Efficacy and safety of retreatment with brentuximab vedotin in patients with relapsed or refractory classical Hodgkin lymphoma or CD30-expressing peripheral T cell lymphoma","volume":"140","author":"Sano","year":"2022","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"322","DOI":"10.6004\/jnccn.2022.0021","article-title":"NCCN Guidelines\u00ae Insights: Hodgkin Lymphoma, Version 2.2022","volume":"20","author":"Hoppe","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/5\/195\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:38:50Z","timestamp":1760107130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/5\/195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":12,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["curroncol31050195"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31050195","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]}}}